Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations

Fabrizio Biundo, C. d'Abramo, M. D. Tambini, H. Zhang, D. Del Prete, F. Vitale, L. Giliberto, O. Arancio, L. D'Adamio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

TAU mutations are genetically linked to fronto-temporal dementia (FTD) and hyper-phosphorylated aggregates of Tau form neurofibrillary tangles (NFTs) that constitute a pathological hallmark of Alzheimer disease (AD) and FTD. These observations indicate that Tau has a pivotal role in the pathogenesis of neurodegenerative disorders. Tau is cleaved by caspases at Aspartate421, to form a Tau metabolite known as δTau; δTau is increased in AD, due to the hyper-activation of caspases in AD brains. δTau is considered a critical toxic moiety underlying neurodegeneration, which initiates and facilitates NFT formation. As Tau is a therapeutic target in neurodegeneration, it is important to rigorously determine whether δTau is a toxic Tau species that should be pharmacologically attacked. To directly address these questions, we have generated a knock-in (KI) mouse called TauDN-that expresses a Tau mutant that cannot be cleaved by caspases. TauDN mice present short-term memory deficits and synaptic plasticity defects. Moreover, mice carrying two mutant Tau alleles show increased total insoluble hyper-phosphorylated Tau in the forebrain. These data are in contrast with the concept that δTau is a critical toxic moiety underlying neurodegeneration, and suggest that cleavage of Tau by caspases represents a negative feedback mechanism aimed to eliminate toxic Tau species. Alternatively, it is possible that either a reduction or an increase in δTau leads to synaptic dysfunction, memory impairments and Tau pathology. Both possibilities will have to be considered when targeting caspase cleavage of Tau in AD therapy.

Original languageEnglish (US)
Pages (from-to)e1198
JournalTranslational Psychiatry
Volume7
Issue number8
DOIs
StatePublished - Aug 8 2017

Fingerprint

Neuronal Plasticity
Caspases
Poisons
Alzheimer Disease
Neurofibrillary Tangles
Dementia
Memory Disorders
Prosencephalon
Short-Term Memory
Neurodegenerative Diseases
Alleles
Pathology
Mutation
Brain
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Biological Psychiatry

Cite this

Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations. / Biundo, Fabrizio; d'Abramo, C.; Tambini, M. D.; Zhang, H.; Del Prete, D.; Vitale, F.; Giliberto, L.; Arancio, O.; D'Adamio, L.

In: Translational Psychiatry, Vol. 7, No. 8, 08.08.2017, p. e1198.

Research output: Contribution to journalArticle

Biundo, F, d'Abramo, C, Tambini, MD, Zhang, H, Del Prete, D, Vitale, F, Giliberto, L, Arancio, O & D'Adamio, L 2017, 'Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations', Translational Psychiatry, vol. 7, no. 8, pp. e1198. https://doi.org/10.1038/tp.2017.165
Biundo, Fabrizio ; d'Abramo, C. ; Tambini, M. D. ; Zhang, H. ; Del Prete, D. ; Vitale, F. ; Giliberto, L. ; Arancio, O. ; D'Adamio, L. / Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations. In: Translational Psychiatry. 2017 ; Vol. 7, No. 8. pp. e1198.
@article{3ffb5e28bbae46929fa269f228fb6c88,
title = "Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations",
abstract = "TAU mutations are genetically linked to fronto-temporal dementia (FTD) and hyper-phosphorylated aggregates of Tau form neurofibrillary tangles (NFTs) that constitute a pathological hallmark of Alzheimer disease (AD) and FTD. These observations indicate that Tau has a pivotal role in the pathogenesis of neurodegenerative disorders. Tau is cleaved by caspases at Aspartate421, to form a Tau metabolite known as δTau; δTau is increased in AD, due to the hyper-activation of caspases in AD brains. δTau is considered a critical toxic moiety underlying neurodegeneration, which initiates and facilitates NFT formation. As Tau is a therapeutic target in neurodegeneration, it is important to rigorously determine whether δTau is a toxic Tau species that should be pharmacologically attacked. To directly address these questions, we have generated a knock-in (KI) mouse called TauDN-that expresses a Tau mutant that cannot be cleaved by caspases. TauDN mice present short-term memory deficits and synaptic plasticity defects. Moreover, mice carrying two mutant Tau alleles show increased total insoluble hyper-phosphorylated Tau in the forebrain. These data are in contrast with the concept that δTau is a critical toxic moiety underlying neurodegeneration, and suggest that cleavage of Tau by caspases represents a negative feedback mechanism aimed to eliminate toxic Tau species. Alternatively, it is possible that either a reduction or an increase in δTau leads to synaptic dysfunction, memory impairments and Tau pathology. Both possibilities will have to be considered when targeting caspase cleavage of Tau in AD therapy.",
author = "Fabrizio Biundo and C. d'Abramo and Tambini, {M. D.} and H. Zhang and {Del Prete}, D. and F. Vitale and L. Giliberto and O. Arancio and L. D'Adamio",
year = "2017",
month = "8",
day = "8",
doi = "10.1038/tp.2017.165",
language = "English (US)",
volume = "7",
pages = "e1198",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Abolishing Tau cleavage by caspases at Aspartate421 causes memory/synaptic plasticity deficits and pre-pathological Tau alterations

AU - Biundo, Fabrizio

AU - d'Abramo, C.

AU - Tambini, M. D.

AU - Zhang, H.

AU - Del Prete, D.

AU - Vitale, F.

AU - Giliberto, L.

AU - Arancio, O.

AU - D'Adamio, L.

PY - 2017/8/8

Y1 - 2017/8/8

N2 - TAU mutations are genetically linked to fronto-temporal dementia (FTD) and hyper-phosphorylated aggregates of Tau form neurofibrillary tangles (NFTs) that constitute a pathological hallmark of Alzheimer disease (AD) and FTD. These observations indicate that Tau has a pivotal role in the pathogenesis of neurodegenerative disorders. Tau is cleaved by caspases at Aspartate421, to form a Tau metabolite known as δTau; δTau is increased in AD, due to the hyper-activation of caspases in AD brains. δTau is considered a critical toxic moiety underlying neurodegeneration, which initiates and facilitates NFT formation. As Tau is a therapeutic target in neurodegeneration, it is important to rigorously determine whether δTau is a toxic Tau species that should be pharmacologically attacked. To directly address these questions, we have generated a knock-in (KI) mouse called TauDN-that expresses a Tau mutant that cannot be cleaved by caspases. TauDN mice present short-term memory deficits and synaptic plasticity defects. Moreover, mice carrying two mutant Tau alleles show increased total insoluble hyper-phosphorylated Tau in the forebrain. These data are in contrast with the concept that δTau is a critical toxic moiety underlying neurodegeneration, and suggest that cleavage of Tau by caspases represents a negative feedback mechanism aimed to eliminate toxic Tau species. Alternatively, it is possible that either a reduction or an increase in δTau leads to synaptic dysfunction, memory impairments and Tau pathology. Both possibilities will have to be considered when targeting caspase cleavage of Tau in AD therapy.

AB - TAU mutations are genetically linked to fronto-temporal dementia (FTD) and hyper-phosphorylated aggregates of Tau form neurofibrillary tangles (NFTs) that constitute a pathological hallmark of Alzheimer disease (AD) and FTD. These observations indicate that Tau has a pivotal role in the pathogenesis of neurodegenerative disorders. Tau is cleaved by caspases at Aspartate421, to form a Tau metabolite known as δTau; δTau is increased in AD, due to the hyper-activation of caspases in AD brains. δTau is considered a critical toxic moiety underlying neurodegeneration, which initiates and facilitates NFT formation. As Tau is a therapeutic target in neurodegeneration, it is important to rigorously determine whether δTau is a toxic Tau species that should be pharmacologically attacked. To directly address these questions, we have generated a knock-in (KI) mouse called TauDN-that expresses a Tau mutant that cannot be cleaved by caspases. TauDN mice present short-term memory deficits and synaptic plasticity defects. Moreover, mice carrying two mutant Tau alleles show increased total insoluble hyper-phosphorylated Tau in the forebrain. These data are in contrast with the concept that δTau is a critical toxic moiety underlying neurodegeneration, and suggest that cleavage of Tau by caspases represents a negative feedback mechanism aimed to eliminate toxic Tau species. Alternatively, it is possible that either a reduction or an increase in δTau leads to synaptic dysfunction, memory impairments and Tau pathology. Both possibilities will have to be considered when targeting caspase cleavage of Tau in AD therapy.

UR - http://www.scopus.com/inward/record.url?scp=85042214094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042214094&partnerID=8YFLogxK

U2 - 10.1038/tp.2017.165

DO - 10.1038/tp.2017.165

M3 - Article

VL - 7

SP - e1198

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 8

ER -